Sex-Specific GLP-1 Brain Atlas Reveals Drug Impact Differences
Glucagon-like peptide 1 (GLP-1) analogs such as semaglutide, liraglutide, and lixisenatide have transformed obesity and diabetes management. A peer-reviewed study published in Brain Medicine (Genomic Press) introduces the first comprehensive sex-specific GLP-1 brain atlas, mapping GLP-1 expression at single-transcript resolution in the murine brain. Led by Vitaly Ryu, Anisa Gumerova, Georgii Pevnev, Tony Yuen, and senior author Mone Zaidi at the Icahn School of Medicine at Mount Sinai, this atlas identifies GLP-1 across 25 distinct brain nuclei, subnuclei, and regions in both sexes, exposing significant geographical differences.
These sex differences in GLP-1 expression are crucial because obesity and diabetes present sex-specific pathological features, and GLP-1 shows stronger effects on appetite suppression, glycemic regulation, and weight loss in females. The findings also open doors to psychiatric applications, including addiction and depression treatments.
The Need for a Sex-Specific GLP-1 Brain Atlas
Despite billions in sales and widespread prescriptions, the precise locations of GLP-1 in the brain—and sex-based variations—remained unclear. "We set out to build a resource that the field has needed for a long time," said Mone Zaidi, senior author and professor at the Icahn School of Medicine at Mount Sinai. "GLP-1 analogs are among the most impactful drug classes to emerge in decades, yet we have lacked a detailed, sex-specific map of where GLP-1 is actually expressed in the brain. This atlas provides that foundation."
GLP-1 agonists mimic the gut hormone GLP-1, which signals satiety, slows gastric emptying, and enhances insulin secretion. In the brain, they act on receptors to regulate feeding behavior and energy balance. Understanding sex-specific expression helps explain why women often experience greater weight loss on these drugs and informs personalized dosing or combinations.
Advanced Methods: RNAscope for Precise Mapping
The team used RNAscope, a highly sensitive technique detecting single mRNA transcripts. They analyzed whole brain sections from three female and three male mice, hybridizing ~20 pairs of transcript-specific double Z-probes to 5-micrometer-thick slices. Blinded observers manually counted transcripts in every tenth section, confirming inter-rater reliability. Probe specificity was validated in the small intestine, pancreas, and medullary nucleus of the solitary tract, with no staining in the kidney.
This overcame challenges of GLP-1's low brain abundance and rapid degradation, providing unprecedented resolution. GLP-1 was detected in the medulla, olfactory bulb, midbrain, pons, hippocampus, hypothalamus, thalamus, and ependymal layer of the third ventricle.
Hindbrain: Profound Sex Differences
The medulla and olfactory bulb showed the highest GLP-1 counts in both sexes, but patterns diverged sharply. In females, top hindbrain densities were in the raphe obscurus nucleus (ROb), ventral solitary tract (SolV), and medial solitary tract (SolM). In males, they were in central (SolCe), intermediate (SolIM), and medial (SolM) solitary tract subnuclei.
Females had higher densities and neuron counts in ROb, SolV (P=0.034), and SolVL (P=0.069 trend). Sex-biased expression appeared in several nuclei: only females showed GLP-1 in ambiguus nucleus, tectospinal tract, ventral cochlear nucleus (posterior), and cuneate nucleus; only males in dorsomedial spinal trigeminal nucleus, intercalated nucleus, paramedian reticular nucleus, SolCe, and spinal trigeminal nucleus (caudal). Highest single-sex peaks: ambiguus in females, SolCe in males.
"What struck us was not just where we found GLP-1 expression, but the degree to which the pattern diverged between females and males in specific hindbrain subnuclei," said Vitaly Ryu, co-first author. "Several medullary nuclei displayed expression in only one sex, which opens entirely new questions about how GLP-1 circuits operate differently in the female and male brain."
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Olfactory Bulb: Unexpected Metabolic Insights
GLP-1 density was significantly higher in males' olfactory bulb (P=0.024), especially granular cell layer (GrO; P=0.031). These interneurons may modulate mitral cell excitability for post-prandial appetite suppression. Food odors trigger insulin release more in males, potentially linked to this. Females' estrogen enhances olfaction, possibly compensating for lower GLP-1. Males' higher GrO GLP-1 might amplify insulin signaling, explaining diet-induced hyperinsulinemia in males but not females.
GLP-1 in a Network of Sexually Dimorphic Peptides
GLP-1 interacts with orexigenic neuropeptide Y (lower in females), anorexigenic POMC (higher activity in females, estrogen-modulated), leptin (additive suppression via solitary tract), and ghrelin (counterbalances). GLP-1 axons in ROb appose serotonergic neurons for autonomic control. Additional sites: midbrain/pons (ventral tegmental area only in females), hippocampus (dentate gyrus), hypothalamus (lateral only in males), thalamus.
Implications Beyond Metabolism: Psychiatric and Alzheimer's Potential
"The implications extend well beyond metabolism," said Zaidi. Ventral tegmental area (reward) GLP-1 only in females and lateral hypothalamus (motivation) only in males suggest psychiatric roles. Detection in Alzheimer's-vulnerable areas like hippocampus supports investigations into neuroinflammation and memory.
Clinically, this underscores monitoring sex-specific responses to GLP-1 agonists. Women may benefit more for weight loss; men for insulin-related issues. Emerging psychiatric uses warrant sex-stratified trials.
Study Limitations and Future Directions
Small sample (n=3/sex) limits power for low-expression areas. Females unstaged for estrous; RNAscope shows transcripts, not function. Findings are hypothesis-generating, conserved across rodents/primates for translation.
This atlas guides precise GLP-1 therapies. Read the open-access article: Ryu V, et al. "Atlas of GLP-1 expression in the mouse brain: Neuroanatomical basis for metabolic and psychiatric effects." Brain Medicine 2026. DOI: 10.61373/bm026a.0006.
What This Means for Patients and Clinicians
Key Takeaways:
- Sex-specific GLP-1 brain mapping explains differential drug responses in obesity/diabetes.
- Females: Stronger hindbrain expression may drive better appetite/weight outcomes.
- Males: Olfactory GLP-1 links to insulin dynamics.
- Psychiatric/Alzheimer's potential requires sex-focused research.
Discuss GLP-1 agonists with your doctor, considering sex, comorbidities. Track symptoms with apps like Shotlee for side effects or adherence. Compare to alternatives like SGLT2 inhibitors, but GLP-1's brain effects are unique. Safety: Common GI issues; rare pancreatitis—monitor closely.
Conclusion
This sex-specific GLP-1 brain atlas demystifies why semaglutide et al. work differently by sex, paving personalized metabolic and brain health therapies. Patients: Share this with providers for informed decisions.
